Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 9/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TTPA | P49638 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2802998 | 0.82 | MEN1 (0.41) | MEN1KMT2ACYP2C9ALOX15CYP2C19 | |
| SCHEMBL23111867 | 0.81 | MEN1 (0.40) | MEN1KMT2ACYP2C9ALOX15CYP2C19 | |
| SCHEMBL2417145 | 0.79 | MEN1 (0.44) | MEN1KMT2ACYP2C9ALOX15CYP2C19 | |
| SCHEMBL8846809 | 0.75 | MEN1 (0.46) | MEN1KMT2ACYP2C9ALOX15CYP2C19 | |
| SCHEMBL12987284 | 0.73 | ACHE (0.44) | MEN1KMT2AACHEL3MBTL1 | |
| SCHEMBL20921400 | 0.72 | PTGS2 (0.34) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL9330344 | 0.70 | MEN1 (0.36) | MEN1KMT2ACYP2C9ALOX15CYP2C19 | |
| SCHEMBL22517795 | 0.69 | PTGS2 (0.40) | TTPAPTGS2CA12CA1CA2 | |
| SCHEMBL3922804 | 0.69 | PTGS2 (0.43) | TTPAPTGS2CA12CA1CA2 | |
| SCHEMBL8846603 | 0.69 | MEN1 (0.49) | MEN1KMT2ACYP2C9ALOX15CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729115-B2 | Valsartan derivatives carrying nitrogen oxide donors for the treatment of vascular and metabolic diseases | CARDIOLYNX AG (CH) | 2014-05-20 | — | — | US | disclosed |
| US-8703800-B2 | Nitrate and diazeniumdiolate derivatives of pioglitazone | CARDIOLYNX AG (CH) | 2014-04-22 | — | — | US | disclosed |
| US-8703800-B2 | Nitrate and diazeniumdiolate derivatives of pioglitazone | CARDIOLYNX AG (CH) | 2014-04-22 | — | — | US | disclosed |
| US-8426597-B2 | Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases | CARDIOLYNX AG (CH) | 2013-04-23 | — | — | US | disclosed |
| EP-2576545-A1 | NITRATE AND DIAZENIUMDIOLATE DERIVATIVES OF PIOGLITAZONE | Cardiolynx AG (CH) | 2013-04-10 | — | — | EP | disclosed |
| US-20130072525-A1 | NITRATE AND DIAZENIUMDIOLATE DERIVATIVES OF PIOGLITAZONE | CARDIOLYNX AG (CH) | 2013-03-21 | — | — | US | disclosed |
| US-20130072525-A1 | NITRATE AND DIAZENIUMDIOLATE DERIVATIVES OF PIOGLITAZONE | CARDIOLYNX AG (CH) | 2013-03-21 | — | — | US | disclosed |
| US-20130041001-A1 | VALSARTAN DERIVATIVES CARRYING NITROGEN OXIDE DONORS FOR THE TREATMENT OF VASCULAR AND METABOLIC DISEASES | CARDIOLYNX AG (CH) | 2013-02-14 | — | — | US | disclosed |
| EP-2377855-B1 | A valsartanamide dinitrate derivative for the treatment of vascular and metabolic diseases | CARDIOLYNX AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011151362-A1 | NITRATE AND DIAZENIUMDIOLATE DERIVATIVES OF PIOGLITAZONE | CARDIOLYNX AG (CH) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011131613-A1 | VALSARTAN DERIVATIVES CARRYING NITROGEN OXIDE DONORS FOR THE TREATMENT OF VASCULAR AND METABOLIC DISEASES | CARDIOLYNX AG (CH) | 2011-10-27 | — | — | WO | disclosed |
| EP-2377855-A1 | A valsartanamide dinitrate derivative for the treatment of vascular and metabolic diseases | Cardiolynx AG (CH) | 2011-10-19 | — | — | EP | disclosed |
| EP-2367803-A1 | NITRATE DERIVATIVES OF CILOSTAZOL FOR THE TREATMENT OF VASCULAR AND METABOLIC DISEASES | Cardiolynx AG (CH) | 2011-09-28 | — | — | EP | disclosed |
| US-20110230520-A1 | NITRATE DERIVATIVES OF CILOSTAZOL FOR THE TREATMENT OF VASCULAR AND METABOLIC DISEASES | CARDIOLYNX AG (CH) | 2011-09-22 | — | — | US | disclosed |
| WO-2010063724-A1 | NITRATE DERIVATIVES OF CILOSTAZOL FOR THE TREATMENT OF VASCULAR AND METABOLIC DISEASES | CARDIOLYNX AG (CH) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130041001-A1 | VALSARTAN DERIVATIVES CARRYING NITROGEN OXIDE DONORS FOR THE TREATMENT OF VASCULAR AND METABOLIC DISEASES | GLS, REN, NAT1 | MEN1 1075/4885KMT2A 3460/4885CYP2C9 277/4885 |
| US-20110230520-A1 | NITRATE DERIVATIVES OF CILOSTAZOL FOR THE TREATMENT OF VASCULAR AND METABOLIC DISEASES | NOS3, NOS2, NOS1 | MEN1 1141/4885KMT2A 3369/4885CYP2C9 1132/4885 |
| US-20130072525-A1 | NITRATE AND DIAZENIUMDIOLATE DERIVATIVES OF PIOGLITAZONE | PPARD, NOS2, PPARA | MEN1 4198/4885KMT2A 4142/4885CYP2C9 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.